Create an Account
  1. Home
  2. Specialty
  3. Cataract & Refractive

Drs. Karpecki and Schaeffer Discuss the Pharmacological Presbyopia Treatment Consensus Statement

Drs Karpecki and Schaeffer Discuss the Pharmacological Presbyopia Treatment Consensus Statement
Media formats available:
Details
Presenters

  • Overview

    Drs. Paul Karpecki and Jack Schaeffer define presbyopia and discuss the impact of presbyopia on a patient’s everyday life. They discuss the incidence and prevalence of presbyopia in the general population, and the need to diagnose it earlier. They also describe efficacy, safety, and comfort considerations for emerging pharmacological presbyopia treatment options. Drs. Paul Karpecki and Jack Schaeffer discuss emerging pharmacological presbyopia treatments, including ocular surface health considerations, as well as how to best implement these treatments in today’s practice.

    This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Define the ideal pre-cataract presbyopia patient for pharmacological treatment, including age ranges, refractive error levels, key demographics, and other clinical and socioeconomic parameters
    • Determine how to diagnose the pre-cataract presbyopia patient
    • Compare and contrast the advantages and disadvantages of the various pharmacological presbyopia treatments, including efficacy, safety, and functionality
    • Identify best practices on how to identify, communicate and educate the pre-cataract patient

    • Accreditation

      Sponsored by:

      Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
      This activity, COPE Activity Number 122236, is accredited by COPE for continuing education for optometrists. 
      This course is approved for .25 hours of CE. 
      Course #:  73469-AS
      Activity ID: 122236

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Paul M. Karpecki, OD, FAAO

      Paul M. Karpecki, OD, FAAO

      Director of Cornea and External Disease
      Kentucky Eye Institute
      Lexington, Kentucky
      Associate Professor
      College of Optometry
      University of Pikeville
      Pikeville, Kentucky


      Jack L. Schaeffer, OD, FAAO

      Jack L. Schaeffer, OD, FAAO

      Past President and Founder
      Chief of Optometry
      Schaeffer Eye Center
      Birmingham, AL


      Paul M. Karpecki, OD, FAAO

      Paul M. Karpecki, OD, FAAO

      Director of Cornea and External Disease
      Kentucky Eye Institute
      Lexington, Kentucky
      Associate Professor
      College of Optometry
      University of Pikeville
      Pikeville, Kentucky


      Jack L. Schaeffer, OD, FAAO

      Jack L. Schaeffer, OD, FAAO

      Past President and Founder
      Chief of Optometry
      Schaeffer Eye Center
      Birmingham, AL


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Paul M. Karpecki, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/AbbVie, Eyenovia, Ocuphire, and Orasis. Stock/Shareholder: Ocuphire and Orasis.

      Jack L. Schaeffer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Mati Therapeutics, Orasis, and Visus. Speaker’s Bureau: Alcon Vision, Allergan, Bausch + Lomb, Mati Therapeutics, Novartis, and Precipt. Stock/Shareholder: Mati Therapeutics, Orasis, Precipt, and Tearfilm.

       Evolve and The Fundingsland Group planners have no financial relationships with commercial interests. 

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free